| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,4 M € | +18.6% | 4,5 M € | -11.4% | 5,1 M € | -15.8% | 6,1 M € | +7.0% | 5,7 M € | -6.0% | 6,1 M € | +0.6% | 6,0 M € | +12.1% | 5,4 M € | -4.5% | 5,6 M € | +9.8% | 5,1 M € | +7.0% | 4,8 M € | +28.8% | 3,7 M € | -7.1% | 4,0 M € | -19.3% | 5,0 M € | +5.9% | 4,7 M € | +0.3% | 4,7 M € | +13.6% | 4,1 M € | |
| Gross margin | 2,8 M € | +28.6% | 2,2 M € | -25.7% | 3,0 M € | -23.8% | 3,9 M € | +19.4% | 3,3 M € | -0.9% | 3,3 M € | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| EBITDA | 1,6 M € | +55.7% | 1,0 M € | -44.1% | 1,8 M € | -32.8% | 2,7 M € | +27.0% | 2,1 M € | -5.7% | 2,3 M € | -19.4% | 2,8 M € | +15.0% | 2,4 M € | -59.5% | 6,0 M € | +199.7% | 2,0 M € | +15.5% | 1,7 M € | +45.8% | 1,2 M € | -8.8% | 1,3 M € | -42.0% | 2,3 M € | +1.2% | 2,2 M € | +94.5% | 1,1 M € | -29.1% | 1,6 M € | |
| Operating profit | 1,4 M € | +113.6% | 647,7 k € | -56.5% | 1,5 M € | -33.8% | 2,2 M € | +24.4% | 1,8 M € | -8.0% | 2,0 M € | -22.5% | 2,5 M € | +14.5% | 2,2 M € | -62.0% | 5,8 M € | +216.8% | 1,8 M € | +9.7% | 1,7 M € | +39.8% | 1,2 M € | +34.8% | 889,1 k € | +172.7% | -1,2 M € | -170.4% | 1,7 M € | +157.6% | 674,3 k € | -44.4% | 1,2 M € | |
| Profit/loss | 1,6 M € | +69.5% | 969,3 k € | -21.3% | 1,2 M € | -22.6% | 1,6 M € | +14.4% | 1,4 M € | -1.1% | 1,4 M € | -24.5% | 1,9 M € | +24.5% | 1,5 M € | -61.2% | 3,9 M € | +206.1% | 1,3 M € | +7.5% | 1,2 M € | +7.2% | 1,1 M € | +73.5% | 630,3 k € | +143.3% | -1,5 M € | -235.2% | 1,1 M € | +797.0% | 120,1 k € | -89.7% | 1,2 M € | |
| Equity | 21,1 M € | +8.5% | 19,4 M € | +5.3% | 18,4 M € | +7.2% | 17,2 M € | +10.2% | 15,6 M € | +9.8% | 14,2 M € | +11.0% | 12,8 M € | +17.0% | 11,0 M € | +15.8% | 9,5 M € | +68.7% | 5,6 M € | +28.9% | 4,4 M € | +36.9% | 3,2 M € | +52.4% | 2,1 M € | +43.3% | 1,5 M € | -50.0% | 2,9 M € | +58.7% | 1,8 M € | +7.0% | 1,7 M € | |
| Total assets | 23,7 M € | +8.1% | 21,9 M € | +5.1% | 20,8 M € | +4.8% | 19,9 M € | +8.0% | 18,4 M € | +9.6% | 16,8 M € | +8.5% | 15,5 M € | +0.1% | 15,5 M € | +7.3% | 14,4 M € | +64.8% | 8,7 M € | +30.2% | 6,7 M € | +33.5% | 5,0 M € | +30.2% | 3,9 M € | -27.4% | 5,3 M € | -26.7% | 7,3 M € | -2.8% | 7,5 M € | -2.9% | 7,7 M € | |
| Cash | 2,5 k € | -78.1% | 11,3 k € | -71.5% | 39,7 k € | -82.3% | 224,6 k € | +300.0% | 56,2 k € | +98.0% | 28,4 k € | +0.7% | 28,2 k € | -52.8% | 59,6 k € | +41.1% | 42,2 k € | -76.8% | 182,1 k € | +30.8% | 139,2 k € | -72.6% | 508,3 k € | -57.6% | 1,2 M € | -8.6% | 1,3 M € | +51.0% | 867,4 k € | +85.9% | 466,6 k € | -37.8% | 750,6 k € | |
| Debts | 1,0 M € | +14.4% | 904,7 k € | -4.2% | 944,4 k € | -30.2% | 1,4 M € | -15.6% | 1,6 M € | +6.3% | 1,5 M € | -12.4% | 1,7 M € | -52.4% | 3,6 M € | -9.3% | 4,0 M € | +79.9% | 2,2 M € | +52.4% | 1,5 M € | +48.2% | 981,2 k € | +32.8% | 738,9 k € | -70.7% | 2,5 M € | -16.3% | 3,0 M € | -28.6% | 4,2 M € | -27.5% | 5,8 M € | |
| Staff | 11,5 | 11,5 | 11,5 | 12,5 | 11,6 | 11,1 | 10,5 | 10,5 | 10,3 | 8,7 | 8,5 | 8,9 | 9,5 | 9,8 | 9,4 | 10,6 | 9,7 | |||||||||||||||||
Public limited company · Woluwe-Saint-Lambert · incorporated on 16/12/2002 · 11,5 ETP
Public limited company profitable and well capitalised. Cash position declining (-78.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
BETAPLUS PHARMA is a Public limited company incorporated in 2002. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Woluwe-Saint-Lambert. It employs on average 11,5 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette